165 results
8-K
EX-99.1
NRBO
NeuroBo Pharmaceuticals Inc
9 May 24
NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results
8:05am
Receptor 119 (GPR119) agonist for treating MASH. This milestone followed closely on the heels of the Safety Review Committee (SRC) approval, allowing … the study to continue without modification, an early indication of the safety of DA-1241. Part 2 of this trial, in combination with sitagliptin, a DPP4
8-K
EX-99.1
NRBO
NeuroBo Pharmaceuticals Inc
17 Apr 24
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating
8:30am
Heon Kim, President and Chief Executive Officer of NeuroBo. “Although the main goal of the SAD part of this study is to assess the safety … , placebo-controlled, double-blind, two-part study to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single
8-K
EX-99.1
NRBO
NeuroBo Pharmaceuticals Inc
16 Apr 24
Other Events
4:30pm
-controlled, Phase 1 clinical trial to evaluate the efficacy and safety of DA-1726 in obese, otherwise healthy subjects Additional Endpoints ▪ Biomarker … changes (PK, PD) ▪ Longer term safety (i.e., AEs, Lab, ECG) Study Design ▪ 3 Period design Titration Period – up to 12 weeks Treatment Period – at least
8-K
EX-99.1
2cy5 gwuj
1 Apr 24
NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
8:30am
8-K
px65g4skqezyeh6qv
1 Apr 24
NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
8:30am
8-K
EX-99.1
2tskw9hgp
28 Mar 24
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
8:01am
8-K
h6n u6ouu
13 Mar 24
Blinded Safety Review Completed for the First 6 Months of the Phase 2a Clinical Trial Conduct; Recommending Trial Continue Without Modification
8:30am
8-K
EX-99.1
v86re9q
13 Mar 24
Blinded Safety Review Completed for the First 6 Months of the Phase 2a Clinical Trial Conduct; Recommending Trial Continue Without Modification
8:30am
8-K
EX-99.1
90k8ejtyeea0ug
4 Mar 24
NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive
7:30am
8-K
EX-99.1
6762gh575pdkj42j
29 Feb 24
NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
8:30am
8-K
EX-99.1
odc958w38im4q
14 Feb 24
Other Events
8:52am
8-K
EX-99.1
jdai2z4cgmptl15qa9jy
1 Feb 24
NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
8:30am
8-K
jpkrpk5s0
18 Jan 24
Full Data Readout Expected in the Second Half of 2024
8:30am
8-K
EX-99.1
4di yv8dlw4
18 Jan 24
Full Data Readout Expected in the Second Half of 2024
8:30am
8-K
EX-99.1
hpol5w
28 Dec 23
NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
9:00am